Abrégé

The present invention relates to the field of in vitro prognosis of neonatal sepsis. More specifically, the present invention relates to the use of indole-3-aldehyde as a predictive biomarker for the risk of a neonate developing sepsis.

Classes IPC  ?

• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Present disclosure discloses an implantable total artificial heart. The artificial heart includes a first pumping chamber, a second pumping chamber and an actuator disposed between the first pumping chamber and the second pumping chamber. The actuator is configured to operate between a first operating state and a second operating state. Further, the artificial heart includes a plurality of first wires wound around the first pumping chamber and the actuator, and/or a plurality of second wires wound around the second pumping chamber and the actuator. Each of the plurality of first and second wires are configured to compress the first and second pumping chambers relative to operation of the actuator for receiving fluid into and pumping fluid out of the first and second pumping chamber. The configuration of the artificial heart is compact, improves durability and mimicking the natural movement of a human tissue for reducing stress on blood and resulting in fewer side effects.

Classes IPC  ?

• A61M 60/196 - Pompes ou dispositifs de pompage implantables, c.-à-d. que le sang est pompé à l’intérieur du corps du patient remplaçant l’ensemble du cœur, p.ex. cœurs artificiels totaux
• A61M 60/268 - Pompes pour le sang à déplacement positif comportant un élément de déplacement agissant directement sur le sang l’élément de déplacement étant souple, p.ex. membranes, diaphragmes ou vessies
• A61M 60/427 - Pompes pour le sang; Dispositifs pour l'actionnement mécanique de la circulation; Pompes à ballon d’assistance circulatoire - Détails concernant l’entraînement pour les pompes pour le sang à déplacement positif la force agissant sur l’élément en contact avec le sang étant hydraulique ou pneumatique
• A61M 60/438 - Pompes pour le sang; Dispositifs pour l'actionnement mécanique de la circulation; Pompes à ballon d’assistance circulatoire - Détails concernant l’entraînement pour les pompes pour le sang à déplacement positif la force agissant sur l’élément en contact avec le sang étant mécanique
• A61M 60/835 - Pompes pour le sang; Dispositifs pour l'actionnement mécanique de la circulation; Pompes à ballon d’assistance circulatoire - Détails structurels autres que ceux relatifs à l’entraînement de la pompe dans les pompes pour le sang à déplacement positif

Abrégé

The present invention provides compositions for modulating an immune response in a subject. The compositions include micelles formed from elastin-like peptides (ELPs) that may be bound to immunomodulators. The invention also provides uses of such micelles as adjuvants. Also provided are pharmaceutical formulations including the compositions for use as medicaments, particularly for use in treating cancers, allergy and infectious disease.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/35 - Allergènes
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The invention relates to a method of estimating a relaxation time (Tl) from gradient echo magnetic resonance images, the method comprising: generating an equation representing a relationship between a relaxation time (Tl) and a Magnetic Resonance Imaging (MRI) signal (5) acquired at an instance after application of one or more RF pulses from a plurality of RF pulses (£) applied after a temporal gap and prior to the acquisition of the MRI signal (5), based on a relaxation factor Ei representing Tl relaxation between two consecutive RF pulses during a repetition time (TR), an additional relaxation factor (El gap) representing additional Tl relaxation caused by the temporal gap, with a duration (Tgap) and a flip angle (a) of the plurality of RF pulses (k), wherein the temporal gap is used for applying preparation pulses that do not influence a longitudinal magnetization of spins in MRI, and wherein the plurality of RF pulses (k) having a pre-defined gap between each other; and estimating the relaxation time (Tl) for a plurality of gradient echo magnetic resonance images acquired based on a relaxation factor, an additional relaxation factor, and a flip angle associated with corresponding gradient echo sequences, based on the equation.

Classes IPC  ?

• G01R 33/561 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne par réduction du temps de balayage, c.à d. systèmes d'acquisition rapide, p.ex. utilisant des séquences d'impulsions écho-planar
• G01R 33/44 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique utilisant la résonance magnétique nucléaire [RMN]
• G01R 33/50 - Systèmes d'imagerie RMN basés sur la détermination des temps de relaxation
• G01R 33/56 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne

Abrégé

B. afzeliiB. afzelii. Advantageously, these antigens allow for unprecedented and unexpectedly high sensitivity and specificity in detection of early Lyme disease.

Classes IPC  ?

• G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus

Abrégé

The invention relates to isolated antisense molecule capable of inhibiting the expression of the LMNA gene in a mammalian cell, wherein said antisense molecule comprises an anti-sense nucleic acid strand which is substantially complementary to a target region of a transcript encoded by the LMNA gene, wherein said antisense nucleic acid strand is at least complementary to SNP rs538089, rs505058 or rs4641 in said target region.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice

Abrégé

The invention relates to isolated antisense molecule capable of inhibiting the expression of the KCNQ1 gene in a mammalian cell, wherein said antisense molecule comprises an anti-sense nucleic acid strand which is substantially complementary to a target region of a transcript encoded by the KCNQ1 gene, wherein said antisense nucleic acid strand is at least complementary to SNP rs1057128, rs8234 or rs17215465 in said target region.

Classes IPC  ?

• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
• C12N 15/79 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
• C12N 15/86 - Vecteurs viraux
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique

Abrégé

The present invention relates to compounds of formula (I) (I) or pharmaceutically acceptable salts and/or solvates thereof. The invention further relates to the use of the compounds of the invention as immunomodulators. The invention further relates to the compounds of the invention for use in the treatment of autoimmune diseases, transplanted organ rejection, graft-versus-host-disease and BOB1-related diseases.

Classes IPC  ?

• C07D 403/04 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
• A61P 37/06 - Immunosuppresseurs, p.ex. médicaments pour le traitement du rejet de greffe
• A61K 31/53 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec trois azote comme seuls hétéro-atomes d'un cycle, p.ex. chlorazanil, mélamine

Abrégé

The invention relates to entospletinib (GS-9973) or a pharmaceutically acceptable salt, ester or derivative thereof for use in the treatment of a viral infection.

Classes IPC  ?

• A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Anaerobutyricum soehngeniiAnaerobutyricum soehngeniiBifidobacteriumBifidobacterium animalissubspecies lactisBifidobacterium breveAnaerobutyricum soehngeniiAkkermansia Akkermansia muciniphilaAnaerobutyricum soehngeniiLactobacillusLactobacillus acidophilusLactobacillus caseiLactobacillus reuteriLactobacillus reuteri or relative thereof.

Classes IPC  ?

• A61K 35/741 - Probiotiques
• A23L 33/135 - Bactéries ou leurs dérivés, p.ex. probiotiques
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

Provided are methods for treating non-Hodgkin lymphoma (NHL) in a human subject comprising administering to the subject a therapeutically effective amount of a BCMA- specific antibody. Also disclosed are compositions comprising a BCMA-specific antibody in an amount that is therapeutically effective for treating non-Hodgkin lymphoma (NHL) in a human subject, and a γ-secretase inhibitor

Classes IPC  ?

• A61P 35/00 - Agents anticancéreux
• A61P 35/02 - Agents anticancéreux spécifiques pour le traitement de la leucémie
• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps

Abrégé

There is provided a Wnt agonist for use in preventing gastrointestinal tract cancer in a subject, wherein the subject has a genetic predisposition to gastrointestinal tract cancer such as FAP as well as a Wnt agonist for preventing or inhibiting the formation of intestinal pre- cancerous lesions or intestinal adenomas.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissance; Régulateurs de croissance
• A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
• A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p.ex. carbazole
• A61P 35/00 - Agents anticancéreux

Abrégé

The invention relates to a kit of parts, consisting of compositions (C1) and (C2) in separate containers, for use in the treatment or prevention of osteoarthritis in a vertebrate, wherein: (a) composition (C1) is a liquid hydrogel formulation comprising a polymer gellant with chemically cross-linkable groups; (b) composition (C2) is an aqueous auxiliary formulation comprising either one or more dissolved cross-linkers Z having two or more reactive groups that can chemically cross-link the polymer gellant by forming covalent bonds; or comprising one or more dissolved compounds Y, selected from the group consisting of oxidant, oxidase, peroxidase and combinations thereof, that initiate or mediate chemical cross-linking of the polymer gellant; wherein said treatment comprises combining compositions (C1) and (C2) to form a liquid hydrogel composition (C3) and administering said liquid hydrogel composition (C3) to the synovial fluid or to the cavity of a synovial joint of the vertebrate, to form a cross-linked hydrogel (C4) in the synovial joint of the vertebrate; or wherein said treatment comprises in a first step administering one of the compositions (C1) or (C2) to the synovial fluid or to the cavity of a synovial joint of the vertebrate and in a second step administering the other of the compositions (C1) or (C2), to form a liquid hydrogel composition (C3) in the synovial joint of the vertebrate that reacts to a cross-linked hydrogel (C4).

Classes IPC  ?

• A61L 27/18 - Matériaux macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
• A61L 27/52 - Hydrogels ou hydrocolloïdes

Abrégé

The invention relates to a pharmaceutical product comprising therapeutically effective amounts of: (a) an ALK inhibitor or an antibody-drug conjugate directed to the ALK receptor, and (b) a TNF-related apoptosis-inducing ligand (TRAIL) receptor agonist.

Classes IPC  ?

• A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p.ex. quinuclidine
• A61P 35/00 - Agents anticancéreux
• A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol

Abrégé

Provided is for a method for determining intra-tumor heterogeneity/ copy number heterogeneity of a tumor of a patient, a computer system for measuring intra-tumor heterogeneity, the computer system programmed to perform (parts of) the method described herein. Also provides is for use of the obtained intra-tumor heterogeneity/ copy number heterogeneity in the diagnosis of a cancer patient, for predicting survival, for stratification of a patients and for following development of a tumor in a patient over time.

Classes IPC  ?

• C12Q 1/6869 - Méthodes de séquençage
• G16B 20/10 - Ploïdie ou détection du nombre de copies

Abrégé

Provided is for a method for determining copy number heterogeneity of a sample obtained from a cell culture, a computer system for measuring copy number heterogeneity, the computer system programmed to perform (parts of) the method described herein.

Classes IPC  ?

• C12Q 1/6869 - Méthodes de séquençage
• G16B 20/10 - Ploïdie ou détection du nombre de copies

Abrégé

VPvarvar V = Vcc V = Vee > Vcc VV.

Classes IPC  ?

• A61M 60/196 - Pompes ou dispositifs de pompage implantables, c.-à-d. que le sang est pompé à l’intérieur du corps du patient remplaçant l’ensemble du cœur, p.ex. cœurs artificiels totaux
• A61M 60/268 - Pompes pour le sang à déplacement positif comportant un élément de déplacement agissant directement sur le sang l’élément de déplacement étant souple, p.ex. membranes, diaphragmes ou vessies
• A61M 60/427 - Pompes pour le sang; Dispositifs pour l'actionnement mécanique de la circulation; Pompes à ballon d’assistance circulatoire - Détails concernant l’entraînement pour les pompes pour le sang à déplacement positif la force agissant sur l’élément en contact avec le sang étant hydraulique ou pneumatique
• A61M 60/438 - Pompes pour le sang; Dispositifs pour l'actionnement mécanique de la circulation; Pompes à ballon d’assistance circulatoire - Détails concernant l’entraînement pour les pompes pour le sang à déplacement positif la force agissant sur l’élément en contact avec le sang étant mécanique
• A61M 60/837 - Aspects des éléments de déplacement souples, p.ex. formes ou matériaux
• A61M 60/873 - Dispositifs d’alimentation en énergie; Convertisseurs à cet effet spécialement adaptés au transfert d’énergie sans fil ou transcutané, p.ex. à la charge par induction

Abrégé

The present invention relates to the use of allogenic fecal matter for the treatment of cachexia and/or cancer, wherein the allogenic fecal matter is obtained from at least one donor subject, wherein the at least one donor subject has a Body Mass Index (BMI) of at least 30 kg/m2, a HOMA-IR value below 2.5 mg/dL and/or an age below 60 years. Fecal matter from said at least one donor subject may be used to treat cancer and/or related conditions.

Classes IPC  ?

• A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
• A61K 35/38 - Estomac; Intestin; Cellules caliciformes; Muqueuse orale; Salive
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes
• A61P 3/04 - Anorexigènes; Médicaments de l'obésité

Abrégé

The present invention is related to human antibodies and antigen-binding fragments of human antibodies that bind to the spike protein of the SARS-CoV-2 virus which is the cause of coronavirus disease 2019 (COVID-19), and therapeutic and diagnostic methods of using those antibodies.

Classes IPC  ?

• C07K 16/10 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus de virus à ARN
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Desulfovibrio speciesDesulfovibrio speciesDesulfovibrio pigeDesulfovibrio fairfieldensis,,Desulfovibrio alaskensis, Desulfovibrio vulgaris, Desulfovibrio vietnamensisDesulfovibrio gigasDesulfovibrio gigas.

Classes IPC  ?

• A61K 31/405 - Acides indole-alkanecarboxyliques; Leurs dérivés, p.ex. tryptophane, indométhacine
• A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée
• A61K 31/20 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique
• A61P 5/48 - Médicaments pour le traitement des troubles du système endocrinien des hormones pancréatiques
• A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

The invention relates to a method of determining the bleeding risk of a subject comprising: a. contacting a first sample from the subject with an activation mixture comprising (I) TIX-5, (II) factor Xa or an activation agent for activating directly or indirectly the conversion of factor X to factor Xa, and (III) a phospholipid mixture, b. determining the value of a coagulation function parameter of said sample, c. comparing the coagulation function parameter with a control value, d. determining the bleeding risk based on a comparison between the value of said coagulation function parameter of said first sample and said control value.

Classes IPC  ?

• G01N 33/86 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir le temps de coagulation du sang

Abrégé

The invention relates to a pharmaceutical product comprising therapeutically effective amounts of: (a) an ALK inhibitor or an antibody-drug conjugate directed to the ALK receptor, and (b) a NF-related apoptosis-inducing ligand (TRAIL) receptor agonist.

Classes IPC  ?

• A61K 31/439 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle le cycle formant une partie d'un système cyclique ponté, p.ex. quinuclidine
• A61P 35/00 - Agents anticancéreux

Abrégé

A method of treating or preventing an intracellular bacterial infection, comprising contacting the cell(s) which are infected with an antibacterial agent and a photosensitizing agent and irradiating the cell(s) with light of a wavelength effective to activate the photosensitizing agent, wherein the antibacterial agent is released into the cytosol of the cell(s) and kills, damages or prevents the replication of bacteria in said cell(s) is described. Related uses, and compositions, products and kits for the same are further described.

Classes IPC  ?

• A61K 38/14 - Peptides contenant des radicaux saccharide; Leurs dérivés
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61P 31/04 - Agents antibactériens
• A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p.ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines

Abrégé

Embodiments of the present invention provide an ancillary device for the cardiopulmonary bypass and a ventilator. In particular, invention relates to a device comprising a first sensor, a second sensor and a controller configured to receive signals from said sensors, and an output means producing an alarm when the outputs from the first and the second sensors are less than a threshold value for more than a threshold amount of time.

Classes IPC  ?

• A61M 1/36 - Autre traitement du sang dans une dérivation du système circulatoire naturel, p.ex. adaptation de la température, irradiation
• A61M 16/00 - Dispositifs pour agir sur le système respiratoire des patients par un traitement au gaz, p.ex. bouche-à-bouche; Tubes trachéaux

Abrégé

An oncotherapeutic product useful for the treatment of cancer. In a preferred embodiment, the oncotherapeutic product is a combination product or kit comprising, the Programmed Death-1 (PD-1) receptor antagonist agent pembrolizumab and the premature stop codon readthrough agent ataluren useful for the treatment of colorectal cancer.

Classes IPC  ?

• A61K 31/4245 - Oxadiazoles
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc

Abrégé

The present invention relates to the use of fecal matter in the treatment of a subject having autoimmune disease, wherein the fecal matter is autologous to the subject, and preferably administered to the small intestine, preferably the duodenum, of the subject. The fecal matter can be one or more constituents of autologous feces, preferably chosen from the group consisting of bacteria, viruses, bacteriophages, fungi, metabolites, microRNAs, proteins, antibodies, and/or antigens.

Classes IPC  ?

• A61K 35/38 - Estomac; Intestin; Cellules caliciformes; Muqueuse orale; Salive
• A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques

Abrégé

A high-performance single-chip, integrated-optics-based OCT system is disclosed, where the length of the reference arm is digitally variable. The reference arm includes a plurality of switch stages comprising a 2×2 tunable wavelength-independent waveguide switch that can direct an input light signal onto either of two different-length output waveguides. In some embodiments, the directional couplers are thermo-optic based. Some embodiments include a solid-state scanning system for scanning a sample signal along a line of object points on the sample under test.

Classes IPC  ?

• G01B 9/02 - Interféromètres

Abrégé

The present invention provides a method of treating or preventing an intracellular bacterial infection, comprising contacting the cell(s) which are infected with an antibacterial agent and a photosensitizing agent and irradiating the cell(s) with light of a wavelength effective to activate the photosensitizing agent, wherein the antibacterial agent is released into the cytosol of the cell(s) and kills, damages or prevents the replication of bacteria in said cell(s). The invention also provides related uses, and compositions, products and kits for the same.

Classes IPC  ?

• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p.ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p.ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
• A61P 31/04 - Agents antibactériens
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire

Abrégé

The invention relates to an isolated, recombinant or synthetic polypeptide comprising an Env polypeptide of an HIV virus, the Env polypeptide comprising at least the amino acid residues K275, D276 and R278, wherein said numbering is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1.

Classes IPC  ?

• C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
• A61K 39/21 - Retroviridae, p.ex. virus de l'anémie infectieuse équine

Abrégé

A low coherence interferometry imaging system comprising a common-path interferometer that is at least partially integrated as part of a planar lightwave circuit is disclosed. Imaging systems in accordance with the present invention are implemented in integrated optics without the inclusion of highly wavelength-sensitive components. As a result, they exhibit less wavelength dependence than PLC-based interferometers of the prior art. Further, the common-path interferometer arrangement of the present invention avoids polarization and wavelength dispersion effects that plague prior-art PLC-based interferometers. Still further, an integrated common-path interferometer is smaller and less complex than other integrated interferometers, which makes it possible to integrate multiple interferometers on a single chip, thereby enabling multi-signal systems, such as plane-wave parallel OCT systems.

Classes IPC  ?

• G01B 9/02 - Interféromètres

Abrégé

The invention relates to a kit of parts comprising an inhibitor of BMP2 and an inhibitor of BMP4 or an inhibitor of BMP2 and BMP4 for use in the treatment of Barrett's Esophagus or for the prevention of esophageal adenocarcinoma. The invention further relates to pharmaceutical composition comprising a kit of parts comprising an inhibitor of BMP2 and an inhibitor of BMP4 or an inhibitor of BMP2 and BMP4 as defined herein and a pharmaceutically acceptable carrier or diluent for use in the treatment of Barrett's Esophagus or for the prevention of esophageal adenocarcinoma.

Classes IPC  ?

• C07K 16/22 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire

Abrégé

The invention relates to a method of diagnosing or screening for 27 -hydroxylase (CYP27A1) deficiency in an animal comprising: determining in a biological sample the intensity signal by mass analysis of at least a bile alcohol glucuronide and a C24- or C27-bile acid or a conjugate thereof, comparing the intensity signals to a control sample or control value, and determining 27-hydroxylase (CYP27A1) deficiency based on said comparison.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

The invention relates to a method for determining the survival prognosis of a patient admitted to an intensive care unit (ICU) or a sepsis patient, comprising steps of determining the expression level of at least BPGM and/or TAP2 in a biological sample of said patient, and compare said expression level(s) with a control and, determine said survival prognosis based on said comparison.

Classes IPC  ?

• C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique

Abrégé

The invention provides devices, apparatuses, systems and methods for treating and ameliorating inflammation of the gut. In particular, the invention provides devices, apparatuses and methods in which a neuromodulatory signal is delivered a splenic nerve and/or superior mesenteric plexus (SMP). The signal is able to treat inflammatory disorders, e.g., colitis, for example in Inflammatory Bowel Disease.

Classes IPC  ?

• A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
• A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque

Abrégé

The invention relates to a method for determining the presence of an unstable atherosclerotic plaque in an individual, comprising the steps of determining the expression level of one or more miRNA(s) selected from the group consisting of miR-223-3p, miR-125b-5p, miR-142-3p and miR-193b-3p in a biological sample from said individual; comparing said expression level(s) with a reference level, and determining presence of said unstable atherosclerotic plaque based on said information. The same miRNA species and miR-499a-5p may be used in the diagnosis of risk of suffering from or developing atherosclerosis.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention provides a method of determining the risk of developing rheumatoid arthritis in a subject comprising the steps of determining in a biological sample from said subject the number and/or frequency of dominant BCR clones, and determining the risk of developing rheumatoid arthritis based on said number of dominant BCR clones, wherein an increase of said number of dominant BCR clones and/or a higher frequency of at least one dominant BCR clone compared to a healthy control indicates an increased risk. In a preferred embodiment, said increased risk is indicated when at least 0.5% of the total number of BCR clones is a dominant BCR clone.

Classes IPC  ?

• G01N 33/564 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to genetically modified HepaRG cells as deposited on 10-5-2016 at the Leibniz-lnstitut DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, under No. DSM ACC3291. The invention further relates to methods of culturing said cells and cell cultures comprising said cells. The invention further relates to uses of the genetically modified HepaRG cells.

Classes IPC  ?

• C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
• C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains
• C12N 15/867 - Vecteurs rétroviraux

Abrégé

The present application relates to an assembly for a joint (1, 2, 3, 4), the joint comprising a joint implant (5, 6) between a proximal segment of a limb that is proximal to the joint and a distal segment of the limb that is distal to the joint and in which the joint is configured to allow rotation of the proximal and distal segments with respect to one another about an axis that intersects a first plane, and to inhibit rotation in the second and third plane, both perpendicular to the first plane, the assembly being for subjecting the joint at predetermined angles of the joint rotation in the second and third plane to a defined bending moment to induce a load to the implant that causes a movement of the implant in relation to the bone of the proximal or distal segments.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61F 2/00 - Filtres implantables dans les vaisseaux sanguins; Prothèses, c.-à-d. éléments de substitution ou de remplacement pour des parties du corps; Appareils pour les assujettir au corps; Dispositifs maintenant le passage ou évitant l'affaissement de structures corporelles tubulaires, p.ex. stents

Abrégé

The invention relates to a miRNA that is useful in the risk stratification of heart failure patients, and especially in the risk stratification of heart failure patients The invention further relates to the use of this miRNA and methods wherein this miRNA is used in expression profiling for risk stratification. The expression of the miRNA of the invention provide information on the risk of re-hospitalization and mortality following the period (generally one year) after the initial sampling (obtaining the biological sample from the patient). The risk stratification provides information about the risk of worsening of the disease and the complications that might come with it.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention relates to a flow cytometry method for determination of size and/or refractive index of substantially spherical single particles, wherein the method comprises the following steps: calibrating a flow cytometer based on light scattering signals, performing a flow cytometry experiment, wherein the flow cytometer experiment comprises illuminating a flow cell of the flow cytometer by an illumination beam and subsequently detecting a first and a second light scattering signal of the single particles in the flow cell, wherein the first and second light scattering signal are differentiated by a polarization state relative to the illumination beam, a wavelength of the illumination beam, and/or a scattering angle, and analyzing data resulting from the flow cytometry experiment for determination of size and/or refractive index of the single particles. The invention also relates to a flow cytometer calibration method.

Classes IPC  ?

• G01N 15/14 - Recherche par des moyens électro-optiques
• G01N 15/10 - Recherche de particules individuelles

Abrégé

The invention relates to a method for determining the risk of suffering from or developing a coronary artery disease (CAD), atherosclerosis or a cardiovascular disease of a smoker, comprising: determining in a biological sample from the smoker the expression level of mi R-124-3p, comparing said expression level with a reference level, and determining said risk based on said comparison.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

A non-destructive method of estimating hematocrit (Hct) of whole blood from a dried blood sample prepared from the whole blood, the method comprising: a) determining the amount of hemoglobin derivatives comprising oxyhemoglobin, met-hemoglobin and hemichrome (total hemoglobin) in a dried blood sample, wherein the sum of the amounts of the hemoglobin derivatives remains constant in the dried blood sample in function of time, and b) estimating the hematocrit from the sum of the amounts of the hemoglobin derivatives, wherein the hematocrit is estimated using a calibration curve providing a correlation between hematocrit and the amount of the hemoglobin derivatives in a dried blood sample. The amount of the hemoglobin derivatives is preferably determined by measuring the reflectance, absorbance, or transmittance of the dried blood sample at the quasi-isosbestic point of the hemoglobin derivatives about 589 nm or at multiple wavelengths within the range of 450 to 750 nm.

Classes IPC  ?

• G01N 21/31 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique

Abrégé

The invention relates to an isolated, recombinant or synthetic polypeptide comprising an Env polypeptide of an HIV virus comprising a gp120 polypeptide portion and at least a gp41 ectodomain polypeptide portion from HIV-1 or a gp125 polypeptide portion and at least a gp36 ectodomain polypeptide portion from HIV-2, wherein said gp120 or gp125 polypeptide portion and said gp41 or gp36 ectodomain polypeptide portion comprise a first cysteine residue at an amino acid position equivalent to amino acid position 49, 50, 51, 71, 72 or 73 and a second cysteine residue at an amino acid position equivalent to amino acid position of a residue selected from the group consisting of: 553, 554, 555, 556, 557, 558, 559, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569 and 570, wherein numbering is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1, and wherein said first and said second cysteine residues form an intermolecular disulfide bond. The invention further relates to an isolated, recombinant or synthetic polypeptide comprising an Env polypeptide of an HIV virus comprising a gp120 polypeptide portion and at least a gp41 ectodomain polypeptide portion from HIV-1 or a gp 125 polypeptide portion and at least a gp36 ectodomain polypeptide portion from HIV-2, wherein said Env polypeptide comprises at least one amino acid residue selected from the group consisting of: 64K and 66R; and 302F, 302W, 304F, 304W, 306L, 307F, 307W, 308L, 315Y, 315K, 3151, 315W, 315F, 315V, 316Y, 316K, 3161, 316F, 316W, and 316V; and 555K or 556K; and 137A, wherein numbering of said at least one amino acid residue is according to the HxB2 reference sequence having the amino acid sequence of SEQ ID NO: 1, and wherein said at least one amino acid residue is at an amino acid position equivalent to the amino acid position of SEQ ID NO: 1.

Classes IPC  ?

• A61K 39/12 - Antigènes viraux
• C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus

Abrégé

A low coherence interferometry Imaging system comprising a common-path Interferometer that is at least partially integrated as part of a planar lightwave circuit Is disclosed. Imaging systems in accordance with the present invention are Implemented in Integrated optics without the inclusion of highly wavelength-sensitive components, As a result, they exhibit less wavelength dependence than PLC-based Interferometers of the prior art. Further, the common-path interferometer arrangement of the present invention avoids polarization and wavelength dispersion effects that plague prior-art PLC-based interferometers. Still further, an integrated common-path Interferometer is smaller and less complex than other integrated interferometers, which makes It possible to Integrate multiple interferometers on a single chip, thereby enabling multi-signal systems, such as plane-wave parallel OCT systems.

Classes IPC  ?

• G01B 9/02 - Interféromètres

Abrégé

The invention relates to a method for diagnosing whether a patient is at risk of suffering from community acquired pneumonia (CAP) comprising steps of: (a) determining the expression levels of FAIM3 and PLAC8 in a biological sample of said patient; (b) comparing said expression levels with a reference control, and (c) determining the risk of suffering from CAP based on said expression levels. In a preferred embodiment, said step (a) comprises determining the ratio of the expression levels of FAIM3 and PLAC8, and step (b) comprises determining said risk based on said ratio.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention provides a flushing system (1) configured to flush the pericardial cavity (PC) of a patient, wherein the system comprises: an infusion liquid outlet (4) to connect a first tube(20) having an infusion liquid lumen to guide a flow of infusion liquid from the system to the pericardial cavity, and an effusion liquid inlet (6) to connect to a second tube (21) having an effusion liquid lumen to guide the effusion liquid flow from the pericardial cavity to the system, a flow rate control system to control the flow rate of the infusion liquid flow at the infusion liquid outlet (4) on the basis of multiple sensor signals, wherein the flow rate control system comprises: a control unit (5) to provide a control signal on the basis of the sensor signals, and a pump device (3) to pump infusion liquid to the infusion liquid outlet (4) at an infusion liquid flow rate, wherein the infusion liquid flow rate is adjustable by the control signal of the control unit (5) and wherein the sensor signals registered by the control unit (5) comprise: an infusion liquid signal representative for the infusion liquid flow to the pericardial cavity, an effusion liquid signal representative for the effusion liquid flow rate from the pericardial cavity, a blood volume signal generated by a hematocrit sensor (12) representative for a blood loss flow rate in the effusion liquid from the pericardial cavity, and a pressure control signal representative for the pressure in the pericardial cavity generated by a pressure sensor positioned inside or in connection with the first tube (20), the second tube (21) or the pericardial cavity. The invention also provides a method of monitoring the blood loss volume or flow rate from the pericardium based on multiple sensor signals as well as, a method of treatment of postoperative cardiac patients in order to reduce the risk of cardiac tamponade, reduce post-operative blood loss and reduce the accumulation of blood and clots in the pericardial cavity, wherein the pericardial cavity of the patient is flushed with a flushing system according to the invention.

Classes IPC  ?

• A61M 3/02 - Clystères; Irrigateurs
• A61M 1/00 - Dispositifs de succion ou de pompage à usage médical; Dispositifs pour retirer, traiter ou transporter les liquides du corps; Systèmes de drainage

Abrégé

The invention relates to methods for quantification of the amount of target mi RNA in biological samples using normalization. In particular, the invention relates to methods for quantifying mi RNAs in serum, whole bold or platelets samples. The invention further relates to kits for quantifying the amount of a target mi RNA in a biological sample.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The invention provides a method for determining whether a patient is sensitive or insensitive to a treatment with a thromboxane A2 inhibitor or a selective COX-1 inhibitor for use in a platelet inhibition treatment comprising the steps of: a. determining the expression level of one or more mi RNA(s) selected from the group consisting of miR-19b-1-5p, miR-1271, and miR-1537-5p, in a sample comprising platelet derived nucleic acids, b. comparing said expression level with a reference level, and c. determining the sensitivity or insensitivity of said subject for a treatment with said thromboxane A2 inhibitor or said selective COX-1 inhibitor based on the information obtained in step b.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
• C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens

Abrégé

The invention relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for in the treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection.

Classes IPC  ?

• A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
• C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
• A01N 43/38 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un atome d'azote comme unique hétéro-atome du cycle des cycles à cinq chaînons condensés avec des carbocycles

Abrégé

The invention provides devices, apparatuses, systems and methods for treating and ameliorating inflammation of the gut. In particular, the invention provides devices, apparatuses and methods in which a neuromodulatory signal is delivered a splenic nerve and/or superior mesenteric plexus (SMP). The signal is able to treat inflammatory disorders, e.g., colitis, for example in Inflammatory Bowel Disease.

Classes IPC  ?

• A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
• A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque

Abrégé

A compound selected from the group consisting of: (i) an inhibitor of Polo-like 1 (PLK1), (ii) an inhibitor of mammalian Ste20-like 1 (MST1), and (iii) an inhibitor of RAF-1, with the proviso that said compound is not an M-CSF antagonist, for use in a treatment of a subject infected with a retrovirus or for prevention of infection with a retrovirus in a subject, preferably wherein said treatment is given before seroconversion.

Classes IPC  ?

• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61K 31/404 - Indoles, p.ex. pindolol
• A61K 31/513 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime ayant des groupes oxo liés directement à l'hétérocycle, p.ex. cytosine
• A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides  contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p.ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p.ex. uridine, acide uridylique, thymidine, zidovudine
• A61K 31/713 - Acides nucléiques ou oligonucléotides à structure en double-hélice
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

The invention relates to an NK3 agonist or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of an atrial arrhythmia. The invention further relates to a composition comprising an NK3 agonist for use in the treatment of a patient suffering from a disease wherein the electrical activity of an atrial heart cell is affected.

Classes IPC  ?

• A61K 38/04 - Peptides ayant jusqu'à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés
• A61P 9/06 - Antiarythmiques

Abrégé

The present invention relates to antibody which binds to an epitope located within the BMPR1 binding region of BMP4.

Classes IPC  ?

• C07K 16/22 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire

Abrégé

The present invention relates to Ig-like molecule which binds to an epitope located within the wrist or the knuckle of BMP4.

Classes IPC  ?

• C07K 16/22 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance

Abrégé

The invention therefore provides a compound effective against Ralstonia pickettii for use in the treatment or prevention of insulin resistance, obesity or type II diabetes of a subject. Preferably, said compound is selected from the group consisting of an antibiotic effective against Ralstonia pickettii, an immunogenic compound capable of producing a protective immune response in a subject, and an antibody which specifically binds to Ralstonia pickettii or a binding fragment thereof. The invention further provides an in vitro method of diagnosis or prediction of insulin resistance, obesity or type II diabetes in a subject, comprising determining the presence of Ralstonia pickettii or the presence of an antibody which specifically binds to Ralstonia pickettii in a test sample of said subject. In another aspect, the invention provides the use of an antibody binding specifically to an antigen of Ralstonia pickettii, a Ralstonia pickettii cell, and/or a nucleic acid hybridizing under stringent conditions to a nucleic acid from Ralstonia pickettii in a method according to the invention. The invention further provides the use of a kit comprising said antibody, a nucleic acid as defined in above, and optionally comprising a Ralstonia pickettii bacteria or a nucleic acid or protein thereof, a further reagent or a conventional kit component.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 16/12 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de bactéries

Abrégé

Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido- deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group ("X") on the methyloxy- carbon. Formula (I), Formula (Ia). These compounds display an increased inhibitory potency towards GCS, and/or an increased inhibitory potency towards GBA2, and/or a decreased inhibitory potency towards GBA1, relative to known deoxynojirimycin derivatives of the same (D-gluco, L-ido or D-galacto) configuration. Therefore, compounds of the present invention are effective in the treatment of diseases which are associated with an irregular level of cytosolic or lysosomal glucosylceramide and/or higher glycosphingolipids, such as a lysosomal storage disorder, such as Gaucher disease, Fabry disease, Tay- Sachs disease, Sandhoff disease, GM1 gangliosidosis, Sialidosis, Niemann Pick disease type C and AMRF, or a symptom of one of the diseases collectively classed as metabolic syndrome, such as obesity, insulin resistance, hyperlipidemia, hypercholesterolemia, polycystic kidney disease, type II diabetes and chronic inflammation, or a neurodenegerative disorder, such as Parkinson disease or Lewy-body dementia.

Classes IPC  ?

• C07D 211/46 - Atomes d'oxygène liés en position 4 comportant un atome d'hydrogène comme second substituant en position 4
• C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
• A61K 31/445 - Pipéridines non condensées, p.ex. pipérocaïne
• A61K 31/4545 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à six chaînons avec l'azote comme hétéro-atome du cycle, p.ex. pipampérone, anabasine
• A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
• A61P 25/16 - Antiparkinsoniens
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal

Abrégé

The invention provides a recombinant collagen or gelatin micro-carrier crosslinked by hexamethylenediisocyanate (HMDIC) comprising stromal cells for use in the treatment of cardiovascular disease. The invention is also directed at applications in which such cell carriers loaded with adipose derived stromal cells are used, for example as injectable cell carrier, for treatment of cardiovascular disease or treatment of damage of other tissues and organs.

Classes IPC  ?

• A61K 35/28 - Moelle osseuse; Cellules souches hématopoïétiques; Cellules souches mésenchymateuses de toutes origines, p.ex. cellules souches dérivées de tissu adipeux
• A61L 27/14 - Matériaux macromoléculaires
• A61L 27/38 - Cellules animales

Abrégé

The invention relates to thrombocidin-derived antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for in the treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection.

Classes IPC  ?

• C07K 14/52 - Cytokines; Lymphokines; Interférons

Abrégé

The invention relates to antimicrobial peptides, pharmaceutical compositions comprising the peptides and to uses thereof for in the treatment or prevention of microbial, bacterial, fungal, viral and parasitic infection.

Classes IPC  ?

• C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères

Abrégé

The invention provides a flushing system (1) configured to flush the pericardial cavity (PC) of a patient, wherein the system comprises: an infusion liquid outlet (4) to connect a first tube(20) having an infusion liquid lumen to guide a flow of infusion liquid from the system to the pericardial cavity, and an effusion liquid inlet (6) to connect to a second tube (21) having an effusion liquid lumen to guide the effusion liquid flow from the pericardial cavity to the system, a flow rate control system to control the flow rate of the infusion liquid flow at the infusion liquid outlet (4) on the basis of multiple sensor signals, wherein the flow rate control system comprises: a control unit (5) to provide a control signal on the basis of the sensor signals, and a pump device (3) to pump infusion liquid to the infusion liquid outlet (4) at an infusion liquid flow rate, wherein the infusion liquid flow rate is adjustable by the control signal of the control unit (5) and wherein the sensor signals registered by the control unit (5) comprise: an infusion liquid signal representative for the infusion liquid flow to the pericardial cavity, an effusion liquid signal representative for the effusion liquid flow rate from the pericardial cavity, a blood volume signal generated by a hematocrit sensor (12) representative for a blood loss flow rate in the effusion liquid from the pericardial cavity, and a pressure control signal representative for the pressure in the pericardial cavity generated by a pressure sensor positioned inside or in connection with the first tube (20), the second tube (21) or the pericardial cavity. The invention also provides a method of monitoring the blood loss volume or flow rate from the pericardium based on multiple sensor signals as well as. a method of treatment of postoperative cardiac patients in order to reduce the risk of cardiac tamponade, reduce post-operative blood loss and reduce the accumulation of blood and clots in the pericardial cavity, wherein the pericardial cavity of the patient is flushed with a flushing system according to the invention.

Classes IPC  ?

• A61M 3/02 - Clystères; Irrigateurs
• A61M 1/00 - Dispositifs de succion ou de pompage à usage médical; Dispositifs pour retirer, traiter ou transporter les liquides du corps; Systèmes de drainage

Abrégé

The invention therefore provides a method for detecting an uncommitted Leydig progenitor cell in a sample of testis cells comprising detecting the presence of CD 146 on the membrane of said cell. The invention further provides a method for selecting an uncommitted Leydig progenitor cell in a sample of testis cells comprising detecting uncommitted Leydig progenitor cell using the above mentioned method of detection and selecting said uncommitted Leydig progenitor cell.

Classes IPC  ?

• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• C12N 5/071 - Cellules ou tissus de vertébrés, p.ex. cellules humaines ou tissus humains

Abrégé

Miltefosin or perifosin for use in the treatment or prevention of inflammatory bowel disease (IBD).

Classes IPC  ?

• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur 
• A61K 31/662 - Acides du phosphore ou leurs esters ayant des liaisons P-C, p.ex. foscarnet, trichlorfon

Abrégé

An arthroscopic instrument assembly (100), comprising: an illumination system (120) for illuminating an operative field, including a light source (122a) configured to produce light having at least one ligament excitation wavelength; an arthroscope (110); an image transmission system (130) configured to transmit a fluorescent image of the operative field at a distal end (112b) of the arthroscope (110) to an image viewing system (150); an image processing system (140) configured to process the fluorescent image as it passes through the image transmission system, so as to provide a false-color fluorescent image of the operative field in which a contrast between ligament and bone structures present in the operative field is enhanced relative to the unprocessed fluorescent image; and an image viewing system (150), operably connected to the image transmission system (130), and including a display (152) configured to enable viewing of the false-color fluorescent image.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61B 1/317 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments pour l'introduction dans des incisions chirurgicales, p.ex. laparoscopes pour les os ou les articulations, p.ex. ostéoscopes, arthroscopes

Abrégé

The present invention provides means and methods for determining whether a hepatitis B patient is susceptible to hepatitis B treatment, comprising determining whether a sample of the patient comprises nucleic acid with nucleotide polymorphisms that are associated with a positive outcome of hepatitis B treatment and/or determining whether a sample of the patient comprises an expression level of carnitine or of a carnitine derivative that is associated with a positive outcome of hepatitis B treatment. Compositions, kits of parts, (micro)arrays and vectors useful for such methods are also herewith provided.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates in general to prevention, reduction or treatment of rejection in transplant patients. In particular the invention relates to the use of SSRIs (selective serotonin reuptake inhibitors) for the prevention, reduction or treatment of rejection in transplant patients, such as blood cell, stem cell, bone marrow, tissue or organ rejection.

Classes IPC  ?

• A61K 31/135 - Amines, p.ex. amantadine ayant des cycles aromatiques, p.ex. méthadone
• A61K 31/4525 - Pipéridines non condensées, p.ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'oxygène comme hétéro-atome du cycle
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p.ex. lignées cellulaires; Tissus; Leur culture ou conservation; Milieux de culture à cet effet

Abrégé

The present invention provides a method of determining the risk of developing metastasis and/or tumor relapse in a colorectal cancer patient, comprising the steps of providing a biological sample of said colorectal cancer patient, and determining in said biological sample the methylation status and/or the expression level of a gene selected from the group consisting of LGR5, APCDD1, ΑΧIΝ2, DKK1, and ASCL2, and determining an increased risk of developing metastasis and/or tumor relapse, under the condition that hypermethylation and/or under expression is determined in a gene selected from the group consisting of LGR5, APCDD1, ΑΧΓΝ2, DKK1, and ASCL2.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

A method of prognosticating progression of Barrett's esophagus in a patient comprising detecting in a sample of esophageal cells from the patient at least one abnormality selected from the group consisting of pi 6 loss, p53 loss, chromosome 7 aneuploidy, and chromosome 17 aneuploidy, which method can further comprise detecting at least one abnormality selected from the group consisting of 20q gain, C-myc gain, and Her2 gain; and a kit comprising (a) a set of probes comprising a probe for pi 6, a probe for p53, a probe for chromosome 7, and a probe for chromosome 17 and (b) instructions comprising determining at least one abnormality selected from the group consisting of p16 loss, p53 loss, chromosome 7 aneuploidy, and chromosome 17 aneuploidy, which kit can further comprise at least one additional probe selected from the group consisting of a probe for 20q, a probe for C-myc, and a probe for Her2 and additional instructions comprising determining at least one additional abnormality selected from the group consisting of 20q gain, C-myc gain, and Her2 gain.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention describes use of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel., as well as pharmaceutical, food, or feed compositions comprising these bacteria, as a medicament, in particular for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as metabolic syndrome, dyslipidemia and type 2 diabetes mellitus as well as insulin resistance in endocrine diseases (e.g.,obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes. Also described is a method for preventing and/or treating insulin resistance and/or insulin resistance-related complications such as dyslipidemia and type 2 diabetes mellitusas well as insulin resistance in endocrine diseases (e.g.,obese subjects with type 1 diabetes mellitus, Cushing's disease and lipodystrophy syndromes)in a subject in need thereof, said method comprising the step of increasing the level of Eubacterium hallii et rel. and/or Alcaligenes faecalis et rel. in the small intestine.

Classes IPC  ?

• A23L 1/03 - contenant des additifs (A23L 1/05, A23L 1/30, A23L 1/308 ont priorité);;
• A23L 1/30 - contenant des additifs (A23L 1/308 a priorité);;
• A23L 2/52 - Addition d'ingrédients
• A61K 35/74 - Bactéries
• A61P 3/04 - Anorexigènes; Médicaments de l'obésité
• A61P 3/06 - Antihyperlipémiants

Abrégé

The present invention relates to novel biomarkers for aging and healthspan, methods and uses thereof, in particular, for determining the biological age of a subject and/or preventing or delaying aging process in a subject, and kits for use in said methods.

Classes IPC  ?

• G01N 33/573 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour enzymes ou isoenzymes
• G01N 33/66 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir les sucres du sang, p.ex. le galactose
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol

Abrégé

This document provides methods and materials involved in assessing and treating humans with LQTS or with a potential mutation in a KCNQ1 nucleic acid that encodes a Kv7.1 potassium channel subunit. For example, methods and materials for determining if a human containing a mutation in a KCNQ1 nucleic acid that encodes a Kv7.1 potassium channel subunit on one allele also contains, on the same allele (a cis relationship) or on the other allele (a trans relationship), a genetic variation (e.g., a SNP) in a 3' UTR of KCNQ1 nucleic acid that creates a miR-378 binding site are provided.

Classes IPC  ?

• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
• A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
• A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester 
• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux

Abrégé

A method and apparatus for dating a dating a body sample, such as blood, includes taking at least one spectroscopic measurement (37) of the sample at least two predetermined positions in the spectrum having spectral characteristics corresponding to at least two predetermined substances present in the sample that have a time varying relationship with each other. A measured relative concentration of each of the predetermined substances is then determined (41) from the measurement, and the measured relative concentrations of the two predetermined substances is compared (43) with a known variation of the relative concentrations of the two predetermined substances over time. A good fit of the measured relative concentrations to the known variation of the relative concentrations is then determined, so as to provide an indication of the age of the sample (44). Alternatively, instead of measuring the relative concentrations of each of the predetermined substances, the rate of change of the relative concentrations is determined.

Classes IPC  ?

• G01N 21/27 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en utilisant la détection photo-électrique
• G01N 21/31 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique

Abrégé

The present invention relates to methods for assessing the susceptibility of a human individual for narrowing of blood vessels after vascular intervention, and especially in-stent restenosis. Especially, the present inventions relates to method for assessing the susceptibility of a human individual for narrowing of blood vessels, after vascular intervention, comprising:1) determining, in a sample originating from said human individual, the genotype of the cyclin-dependent kinase inhibitor p27kip1 encoding gene and/or nuclear receptor Nurr1 encoding gene; and 2) establishing the susceptibility of a human individual for narrowing of blood vessels after vascular intervention based on said determination.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention provides means and methods for counteracting and/or preventing aggregation of a polyQ protein. Further provided are improved poly constructs which are, amongst other things, useful for testing assays. According to the invention, several peptidases like, e.g. tripeptidyl peptidase II (TPPII), appear to be capable of cleaving long polyQ peptides comprising at least 45 glutamine residues. Hence, according to the invention, administration of such peptidases to an individual suffering from a polyQ expansion disorder results in degradation of long polyQ peptides.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
• A61K 38/48 - Hydrolases (3) agissant sur des liaisons peptidiques (3.4)
• C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
• G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
• A61P 25/14 - Médicaments pour le traitement des troubles du système nerveux pour traiter les mouvements anormaux, p.ex. chorée, dyskinésie

Abrégé

The present invention relates to methods for assessing the susceptibility of a human individual for narrowing of blood vessels after vascular intervention, and especially in-stent restenosis. Especially, the present inventions relates to method for assessing the susceptibility of a human individual for narrowing of blood vessels, after vascular intervention, comprising: 1) determining, in a sample originating from said human individual, the genotype of the cyclin-dependent kinase inhibitor p27kip1 encoding gene and/or nuclear receptor Nurr1 encoding gene; and 2) establishing the susceptibility of a human individual for narrowing of blood vessels after vascular intervention based on said determination.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention relates to a binding compound which binds to human APRIL. More specifically the invention provides, compositions of anti-APRIL specific antibodies and methods to use such antibodies in modulating the biological activity APRIL, particularly in inflammatory diseases, inhibition of cell proliferation and cancer.

Classes IPC  ?

• A61K 39/395 - Anticorps; Immunoglobulines; Immunsérum, p.ex. sérum antilymphocitaire
• C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

The present invention relates to a drug delivery system for use in the treatment of vascular and vessel-related pathologies, comprising a drug delivery platform that comprises at least one compound capable of exerting an effect on the formation and/or maintenance of a thrombus in the vessel to be treated. The platform is preferably formed by liposomes that are sterically stabilized by grafting of poly(ethylene glycol) onto the liposome surface. The liposomes may further comprise photosensitizers and targeting molecules. The liposomes may be thermosensitive. The compound is suitably tranexamic acid. The drug delivery system is preferably used for the treatment of port wine stains.

Classes IPC  ?

• A61K 9/127 - Liposomes
• A61K 31/198 - Alpha-amino-acides, p.ex. alanine, acide édétique (EDTA)
• A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament

Abrégé

A method and apparatus for dating a body sample, for example a sample of body fluid involves taking a series of spectroscopic measurements of the sample, each measurement in the series including at least two predetermined positions in the spectrum. The positions have spectral characteristics corresponding to two or more predetermined substances present in the sample that have a time varying relationship with each other. The measurements in the series are spaced in time. A concentration of each of the substances present in the sample is then determined from each of the spectroscopic measurements at each point in time. Next, a ratio of the concentrations of the two predetermined substances at each point in time is determined and then the ratios of the concentrations of the two predetermined substances over time are analysed to estimate when the concentrations of the two substances were at a limit of their concentrations, thereby providing an indication of the age of the sample. The sample may be blood, which may be either within the body (e.g. as a bruise), or external to the body.

Classes IPC  ?

• A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
• A61B 5/103 - Dispositifs de mesure pour le contrôle de la forme, du dessin, de la dimension ou du mouvement du corps ou de parties de celui-ci, à des fins de diagnostic
• G01N 21/31 - Couleur; Propriétés spectrales, c. à d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes en recherchant l'effet relatif du matériau pour les longueurs d'ondes caractéristiques d'éléments ou de molécules spécifiques, p.ex. spectrométrie d'absorption atomique
• G01N 33/487 - Analyse physique de matériau biologique de matériau biologique liquide
• G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang

Abrégé

The present invention relates to compounds according to formula (I) : wherein R2 is absent or a linking moiety and R3 is selected from the group consisting of anti- inflammatory agents and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising compounds of formula (I) and the use of these pharmaceutical compositions for the treatment or prophylaxis of chronic inflammatory diseases, in particular those that are caused by chronically activated macrophages. The chronic inflammatory disease is in particular atherosclerosis, (rheumatoid) arthritis, an (auto) immune disease.or sarcoidosis.

Classes IPC  ?

• C07H 15/18 - Radicaux acycliques substitués par des carbocycles
• C07H 15/203 - Carbocycles monocycliques autres que des cycles cyclohexane; Systèmes carbocycliques bicycliques
• A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
• A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]

Abrégé

The current invention provides a process for determining the TCR or BCR receptor gene rearrangements and allows visualization of the repertoire of V(D)J rearranged CDR3 domains on an oligonucleotide array on a solid carrier. The method visualizes the end-result of the V(D)J recombination process and in particular the delet ion and insertion process that takes place in the NDN hypervariable region, where 1 up to 13 nucleotides are deleted from the V, D and/or J gene segments, by using a labeled annealer oligonucleotide that hybridizes on or in close proximity of the NDN region. The method allows detection of the full repertoire or a selected part of the repertoire, by choosing and combining primers that are specific for certain V, D and/or J gene segments flanking the CDR3 on either side. The method of the invention may be used or applied for the diagnosis of an immune response against a pathogen, allergen or auto-allergen.

Classes IPC  ?

• C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques

Abrégé

The present invention discloses a therapeutic target for the treatment of cyst ic fibrosis. It was found that inhibition of non-lysosomal glucosylceramidase (GBA2) sufficiently restores chloride current in cells from CF patients carrying the common delF508-CFTR mutation. With the catalytic centre (4) of the enzyme positioned on top of the membrane bilayer face particularly potent inhibitors are found in deoxynojirimycin derivatives having a group that is capable of inserting in the membrane bilayer.

Classes IPC  ?

• C07H 15/12 - Radicaux acycliques non substitués par des structures cycliques liés à un atome d'azote d'un radical saccharide
• A61K 31/70 - Hydrates de carbone; Sucres; Leurs dérivés
• A61P 43/00 - Médicaments pour des utilisations spécifiques, non prévus dans les groupes

Abrégé

The invention provides improved rtTA and single chain rtTA variants and uses thereof for inducible expression of a nucleic acid of interest. Nucleic acid sequences comprising an improved rtTA and/or sc rtTA sequence according to the invention are also provided, as well as vectors, replicons and cells comprising such nucleic acid sequences.

Classes IPC  ?

• C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
• C12N 15/867 - Vecteurs rétroviraux
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 7/01 - Virus, p.ex. bactériophages, modifiés par l'introduction de matériel génétique étranger
• C07K 14/245 - Escherichia (G)
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique

Abrégé

The present invention relates to the use of an agonist of one or more of the nuclear receptors TR3, MINOR and NOT for the preparation of a medicament for the treatment of cardiovascular disease, in particular in-stent restenosis and/or vein-graft disease. The invention further relates to medical devices, such as stents and cuffs, that are coated with the agonist or in which the agonist is incorporated and which are for use in the treatment of in-stent restenosis or vein-graft disease.

Classes IPC  ?

• A61K 31/404 - Indoles, p.ex. pindolol
• A61F 2/06 - Vaisseaux sanguins
• A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p.ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénal